MassDevice.com +5 | The top 5 medtech stories for August 24, 2016

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Syneron Candela dumps Olympic swimmer Ryan Lochte Syneron Candela this week severed its ties with Olympic swimmer Ryan Lochte, who was a spokesman for the aesthetic device company’s Gentle Hair Removal brand. “We hold our employees to high standards, and we expect the same of our business partners,” Yokneam, Israel-based Syneron Candela said. “We wish Ryan well on his future endeavors and thank him for the time he spent supporting our brand.” Read more 4. SRS Medical launches Spanner prostate device study SRS Medical Systems said today it enrolled the 1st patients in an FDA investigational device exemption study as it seeks to expand the indications for its Spanner temporary prostatic stent. The Spanner device consists of a pair of anchors and a silicone tube and is designed to reduce resistance in the bladder neck and prostatic urethra without stenting the external sphincter, SRS said. It’s blind, anesthesia-free implantation procedure is similar to that for a Foley catheter, according to the company. Read more 3. Senators press ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: News Well Plus 5 Source Type: news

Related Links:

Conclusion: The increases in the incidence of different types of cancer in the past decade could be due to the revolutionary change in socioeconomic status that has occurred in Saudi Arabia; therefore, a national plan should be established for cancer prevention, screening and therapy. Concerning mortality, the decrease in its percentage among elderly people could be due to biological factors that should be investigated in the future. PMID: 30520511 [PubMed - in process]
Source: Saudi Medical Journal - Category: Middle East Health Tags: Saudi Med J Source Type: research
Lung cancer is a major health concern worldwide, but new immunotherapeutic treatments for lung cancer have shown great promise and the prognosis for many severe cancers including lung cancer has been improving. In May 2017, the Food and Drug Administration approved pembrolizumab, a therapeutic antibody that blocks lymphocytic programmed death-1 (PD-1), as a first-line treatment for any solid tumor with specific genetic features. Pembrolizumab is a therapeutic antibody that blocks lymphocytic PD-1, the ligand of which (PD-L1) is expressed on tumor cells and which can prevent the immune system from recognizing and destroying...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: CASE REPORTS Source Type: research
CONCLUSION: Certain miRNAs can be used as biomarkers for early diagnosis of bladder cancer. PMID: 30507304 [PubMed - as supplied by publisher]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Authors: Zhang WT, Zhang ZW, Guo YD, Wang LS, Mao SY, Zhang JF, Liu MN, Yao XD Abstract It has become increasingly clear that the development of cancer, a multifactorial disease, cannot be explained by a single molecule or gene mutation. As a new discipline, metabolomics focuses on the body's metabolite changes, and attempts to find differences to explain the development of cancer; it has proven to be effective and credible. Metabolic studies of bladder cancer (BCa) lag behind those of other tumors. This review systematically outlines the specific process of metabolomics and the use of metabolomics in BCa studies i...
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
The objective of this review is to dissect recent insights into inter- and intratumor heterogeneity (ITH) in MIBC, with emphasis on the clinical implications of this heterogeneity for biomarker-driven strategies and the development of new therapies.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Seminars Article Source Type: research
Condition:   Bladder Cancer Intervention:   Drug: Durvalumab Sponsors:   Canadian Cancer Trials Group;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: February 2019Source: Cancer Epidemiology, Volume 58Author(s): Elio Mazzone, Sophie Knipper, Francesco A Mistretta, Zhe Tian, Felix Preisser, Andrea Gallina, Denis Soulieres, Derya Tilki, Francesco Montorsi, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Juan Wisnivesky, Pierre I. KarakiewiczAbstractBackgroundPatients with organ confined muscle-invasive bladder cancer (MIBC) who are candidates for radical cystectomy (RC) should receive neoadjuvant chemotherapy (CHT). However, the most contemporary CHT use rates indicate low adherence to these guidelines. We tested contemporary neoadjuvant CHT rates and ...
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Purpose The intensity of prostate-specific membrane antigen (PSMA) expression increases as the tumor grade increases and the uptake of Ga-68-PSMA is higher in high-grade tumors. The aim of the present study was to evaluate the correlation of preoperative tracer uptake of primary tumor to Gleason Score in patients who underwent prostatectomy. Patients and methods We retrospectively evaluated 141 patients who had Ga-68-PSMA positron emission tomography/computed tomography (PET/CT) imaging and who underwent prostatectomy. All patients had a diagnosis of prostate cancer on the basis of 10–24 cores transrectal ultras...
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: ORIGINAL ARTICLES Source Type: research
Conclusions: This study demonstrates superiority in DFS for NC compared to AC. The positive prognostic impact of complete pathological response to NC was confirmed. PMID: 30510914 [PubMed]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Front Oncol Source Type: research
Conclusions: Our study demonstrates a novel mechanistic link between the epigenetic perturbation of SAT1 and ASS1 and cancer metabolism in cisplatin-resistant bladder cancer cells. These findings suggest potential utility of SAT1 and ASS1 as predictive biomarkers in re-sensitizing bladder cancer to chemotherapy and personalizing therapy.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
More News: Anesthesia | Anesthesiology | Bladder Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Eyes | Liver | Medical Devices | Middle East Health | Study | Urology & Nephrology